

SUPPLEMENTARY

Supplementary Table 1. Comparison of clinical characteristics across baseline RA treatment categories.

	(a) No DMARD	(b) nbDMARD	(c) b/tsDMARD	p-value
N	29	30	13	
Demographics				
Age, years	56.6 ±15.4	54.1 ±16.8	61.7 ±7.92	0.323
Female, N (%)	18 (62.1)	25 (83.3)	11 (84.6)	0.136
Race, N (%)				
White	19 (65.5)	20 (66.7)	12 (92.3)	0.173
Black	5 (17.2)	7 (23.3)	1 (7.7)	0.518
Other	5 (17.2)	1 (3.3)	0 (0.0)	0.122
RA factors				
RA duration, median years [IQR]	0.05 [0.01, 1.47]	6.77 [1.89, 11.6]	5.47 [4.07, 16.0]	<0.001
Seropositive, N (%)	24 (82.8)	24 (82.8)	11 (84.6)	1.000
CCP positive, N (%)	21 (72.4)	22 (75.9)	11 (84.6)	0.718
RF positive, N (%)	22 (75.9)	20 (71.4)	8 (61.5)	0.651
RA clinical measures				
hsCRP, mg/L median [IQR]	8.50 [5.50, 18.5]	10.0 [6.00, 24.0]	6.00 [3.00, 12.0]	0.466
ESR, mm/hr	44.1 ±30.8	38.7 ±29.1	25.5 ±19.3	0.176
Smoking history, N (%)	16 (55.2)	15 (50.0)	7 (53.8)	0.951
DAS28-CRP3	4.69 ±1.20	4.94 ±1.63	4.96 ±1.32	0.774
HAQ	1.34 ±0.73	1.35 ±0.62	0.95 ±0.41	0.135

Mean ±SD shown unless otherwise noted. Fischer's exact test used to test for differences across CTAPs for binary variables; One-way ANOVA used for continuous variables.

(a) Not on a DMARD at baseline visit; (b) Taking one or more nbDMARDs, not on a concurrent b/tsDMARD; (c) On a b/tsDMARD and could be on a concurrent nbDMARD.